Mereo BioPharma Group plc, a multi-asset biopharmaceutical company focused on the acquisition, development and commercialization of innovative therapeutics that aim to improve outcomes for patients with rare and specialty diseases, today announced the appointment of Wills Hughes-Wilson as Head of Patient Access and Commercial Planning.
EU-Commission appoints Jean-Eric Paquet
AppointmentsPaquet is a French national who since November 2015 has served as one of the three Deputy Secretaries-General of the Juncker Commission, and has now been been appointed as Director General of DG Research and Innovation
Mereo BioPharma Appoints Wills Hughes-Wilson
AppointmentsMereo BioPharma Group plc, a multi-asset biopharmaceutical company focused on the acquisition, development and commercialization of innovative therapeutics that aim to improve outcomes for patients with rare and specialty diseases, today announced the appointment of Wills Hughes-Wilson as Head of Patient Access and Commercial Planning.
Bavarian Nordic and AZ combine cancer jab with durvalumab
Latest NewsAstraZeneca (AZ) and Bavarian Nordic (BN) combine BNs cancer vaccine CV301 and AZs PD-L1 checkpoint blocker durvalumab in an investigator-sponsored trail to check synergistic effects in patients with colorectal and pancreatic cancer overexpressing CEA and MUC-1.
EMA recommends two orphan drugs for approval
Latest NewsThe European Medicines Agencys (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended three medicines, two thereof orphan drugs, at its February 2018 meeting.
Bioeconomy: Bringing in the public
Latest NewsEverybody wants green production. Bioeconomy progress, however, must become more visible to consumers and let the civil society get involved to ensure socially robust innovation and perception, according to the BioBioSTEP project.
New Screening method for Antibiotic Discovery Pipeline
Latest NewsA new method that determines the mode of action underlying antimicrobial compounds could help overcome a major stumbling block in the ongoing effort to discover new antibiotics. Using it, reseachers from ETH Zurich zeroed in on compounds directed against tuberculosis.
App design for the cellular processor
BackgroundSince the earliest attempts at genetic engineering, scientists have sought to influence cell behaviour and development through the introduction of foreign genetic material. Synthetic biologists are now taking the idea to a whole new plane with app-like DNA-based software programs that turn cells into diagnostic sensors, therapeutic entities or tissue generators.
Cullinan Oncology partners with MAB Discovery
Latest NewsVirtual oncology company Cullinan Oncology, LLC has selecteed monoclonal antibody provider MAB Discovery GmbH (Neuried) to develop the first candidate of a target portfolio of 8-10 novel antibody therapeutics.
Sigurdur Olafsson appointed CEO of Hikma
AppointmentsHikma Pharmaceuticals today announces its Board of Directors has appointed Sigurdur (Siggi) Olafsson as Chief Executive Officer. Mr Olafsson will also join Hikmas Board of Directors as an executive director, subject to election at the next annual general meeting in May 2018.
Locking malaria parasites into red blood cells
Latest NewsUK researchers headed by Michael Blackman have found out that a proteolytic cascade regulates release of merozoites of the human malaria parasite Plasmodium falciparum from host red blood cells. Inhibitition paves the way to block the parasites egress.